Inside Precision Medicine

Clinical OMICs has transformed into Inside Precision Medicine. Inside Precision Medicine stands as the sole global media outlet dedicated to covering all aspects of precision medicine. It takes a broad view while also delving into the intricate and interconnected challenges that shape this field. With its main magazine, real-time website, a range of eNewsletters, and a variety of engaging broadcast events and multimedia content, Inside Precision Medicine serves as the essential platform for robust discussions and insights that encompass technological advancements as well as complex socio-economic and public policy matters. It also aims to provide practical solutions to the gaps that exist among various stakeholders. Inside Precision Medicine is committed to innovative thinking and actively contributing to genuine progress and change, with a focus on enhancing and streamlining the precision medicine process for the benefit of patients in need. Our main focus areas include Translational Research, Molecular Diagnostics, Informatics, and Patient Care, alongside broader coverage of Disease Indications and Payer/Regulatory topics. Our top-notch content is designed to inform, educate, and enlighten a diverse audience of researchers, pathologists, clinicians, executives, and other professionals in the field.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#545448

United States

#231634

Health/Health Conditions and Concerns

#607

Traffic sources

Monthly visitors

Articles

First Circadian Clock Drug Clears Phase I, Targets Glioblastoma Stem Cells

1 day ago | insideprecisionmedicine.com | Chris Anderson

Researchers at the Keck School of Medicine of USC have found a compound that disrupts the internal clockwork of glioblastoma stem cells, showing safety in humans and promising results in a Phase I clinical trial. Results from the trial, published in Neuro-Oncology, focused on SHP1705, a compound that activates specifically CRY2, a chryptochrome protein, to suppress the transcriptional activity of BMAL1 and CLOCK, key components of the circadian clock machinery.
Simple Mouth Swab Quickly Optimizes IVF Hormone Choice

1 day ago | insideprecisionmedicine.com | Anita Chakraverty

A mouth swab that reveals a woman’s genetic makeup within an hour can help decide the best form of a fertility hormone she should receive to maximize her chances of pregnancy, new research reveals. The findings, in Frontiers in Endocrinology, reveal the benefits of a genotype-guided approach to fertility treatment, and particularly the choice of gonadotropin.
New Biomarkers of Treatment Resistance in Metastatic Prostate Cancer Found

2 days ago | insideprecisionmedicine.com | Chris Anderson

Researchers at the Palacký University in Czechia have discovered blood-based biomarkers that can predict failure of treatment in patients with both metastatic hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC) prostate cancer.
Gene Regulation Does Little to Explain Protein Differences Between Sexes

3 days ago | insideprecisionmedicine.com | Anita Chakraverty

While protein levels often vary between men and women, research suggests that just a small percentage of these differences are regulated by genes. A new study indicates that other intrinsic factors, such as hormone levels, as well as extrinsic factors such as lifestyle and risk-factor profiles, play a greater role in regulating the human proteome. The findings, published in Nature Communications, could impact the development of precision medicines.
Faeth Therapeutics Proves Three-Pronged Approach to Cancer, Preclinically

3 days ago | insideprecisionmedicine.com | Jonathan Grinstein

With its many blades that can cut through cancer from all sides, a Swiss Army knife is a better strategy than a single, exact surgical tool. That vision drives Faeth Therapeutics, a biotechnology company integrating cutting-edge therapies with dietary interventions to rewrite the rules for treating complex cancers like endometrial and breast cancer.
Cardiovascular Disease Risk Rises with Lp(a) Levels, New Study Suggests

3 days ago | insideprecisionmedicine.com | Malorye Allison Branca

The largest study ever conducted on individuals with cardiovascular disease finds that in those with atherosclerotic cardiovascular disease (ASCVD), risk of recurrent cardiovascular events continues to rise across all ascending levels of Lp(a), with no indication of risk plateauing. This finding is contrary to earlier research. These findings were presented on May 7th at the European Atherosclerosis Society (EAS). They were simultaneously published in the European Heart Journal.
Early Menopause Increases Metabolic Liver Disease Risk

3 days ago | insideprecisionmedicine.com | Helen Albert

Women who experience menopause before the age of 50 are at increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD), as well as associated risk factors such as prediabetes, obesity, high blood pressure, and abnormal lipid levels in the blood.
GLP-1 Receptor Agonists Can Lower Cancer Risk Beyond Weight Loss

3 days ago | insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck

GLP-1RAs, first-generation weight-loss medications, such as liraglutide—known by the brand names Victoza and Saxenda—and exenatide—marketed under the names Byetta and Bydureon—seem to have anti-cancer benefits beyond weight loss, compared to weight loss surgery. This new study was led by researchers of Clalit Health Services in Tel Aviv, Israel, and the Hasharon Hospital, Rabin Medical Center in Petah Tikva, Israel.
Cell Death Blocking Protein Discovery Could Lead to Next-Gen Parkinson's Treatments

3 days ago | insideprecisionmedicine.com | Chris Anderson

A team of scientists in Australia has discovered a small molecule that selectively blocks a key protein involved in cell death, a finding that could lead to the development of treatments for neurodegenerative conditions such as Parkinson’s disease and Alzheimer’s disease (AD).
A Genetic Risk Score for GLP-1 Agonist-Related Nausea

6 days ago | insideprecisionmedicine.com | Malorye Allison Branca

A team led by researchers at Mayo Clinic have used proprietary algorithms and genetic data to develop a risk score that predicts which patients are most likely to experience GI side effects from GLP-1 agonists such as Wegovy and Zepbound. Such effects impact up to 70% of patients. Nausea is the most common reason people discontinue GLP-1s. In this study, patients with certain genetic markers were more than twice as likely to experience nausea from GLP-1s compared to others (68% vs. 30%).